Combining Anti-tumor Alkyl-Phospholipid Analogs and Radiotherapy: Rationale and Clinical Outlook

ISSN: 1875-5992 (Online)
ISSN: 1871-5206 (Print)


Volume 16, 12 Issues, 2016


Download PDF Flyer




Anti-Cancer Agents in Medicinal Chemistry

Formerly: Current Medicinal Chemistry - Anti-Cancer Agents

This journal supports open access

Aims & ScopeAbstracted/Indexed in

Ranking and Category:
  • 27th of 59 in Chemistry, Medicinal

Submit Abstracts Online Submit Manuscripts Online

Editor-in-Chief:
Michelle Prudhomme
Universite Blaise Pascal - C.N.R.S
Aubiere Cedex
France


View Full Editorial Board

Subscribe Purchase Articles Order Reprints

Current: 2.722
5 - Year: 2.849

Combining Anti-tumor Alkyl-Phospholipid Analogs and Radiotherapy: Rationale and Clinical Outlook



Anti-Cancer Agents in Medicinal Chemistry, 14(4): 618-628.

Author(s): Marcel Verheij, Wouter H. Moolenaar and Wim J van Blitterswijk.

Affiliation: Department of Radiation Oncology, The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands.

Abstract

Our improved understanding of the molecular processes that determine cellular sensitivity to ionizing radiation has accelerated the identification of new targets for intervention. Indeed, novel agents have become available for combined clinical use to overcome radioresistance and increase the therapeutic ratio of radiotherapy. Synthetic alkyl-phospholipid analogs (APLs), such as edelfosine, ilmofosine, miltefosine, perifosine and erucylphosphocholine, are a novel class of anti-tumor agents that target cell membranes to induce growth arrest and apoptosis. In addition, APLs strongly enhance the cytotoxic effect of radiation in preclinical models making these compounds attractive candidates as clinical radiosensitizers. In this review, we will discuss mechanisms of action underlying the rationale to combine APLs with radiotherapy and highlight the clinical perspective of this novel combined modality treatment.

Keywords:

Alkyl-phospholipids, anti-cancer agents, apoptosis, (Pre-)clinical, radiosensitizer, radiotherapy, signal transduction.



Purchase Online Order Reprints Order Eprints Rights and Permissions




Article Details

Volume: 14
Issue Number: 4
First Page: 618
Last Page: 628
Page Count: 11
DOI: 10.2174/1871520614666140309224145
Price: $58
Advertisement

Related Journals




Webmaster Contact: urooj@benthamscience.org Copyright © 2016 Bentham Science